Insider Selling: Omnicell, Inc. (NASDAQ:OMCL) CEO Sells $279,407.70 in Stock

Omnicell, Inc. (NASDAQ:OMCL) CEO Randall A. Lipps sold 3,718 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $75.15, for a total transaction of $279,407.70. Following the sale, the chief executive officer now directly owns 152,116 shares in the company, valued at approximately $11,431,517.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

OMCL stock opened at $70.29 on Friday. The company’s 50 day moving average price is $67.18 and its 200 day moving average price is $72.69. Omnicell, Inc. has a fifty-two week low of $54.24 and a fifty-two week high of $94.85. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of 62.20, a PEG ratio of 2.82 and a beta of 1.03.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.37 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.14. The company had revenue of $199.62 million for the quarter, compared to analyst estimates of $182.16 million. Omnicell had a net margin of 5.42% and a return on equity of 9.21%. The firm’s revenue was down 8.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 earnings per share. As a group, sell-side analysts forecast that Omnicell, Inc. will post 1.68 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on OMCL. Craig Hallum reduced their price target on shares of Omnicell from $102.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday. Piper Sandler reduced their price target on shares of Omnicell from $76.00 to $70.00 and set a “neutral” rating on the stock in a research report on Wednesday. Benchmark cut their target price on shares of Omnicell from $96.00 to $82.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Stephens assumed coverage on shares of Omnicell in a research note on Monday, July 6th. They set an “overweight” rating and a $90.00 target price on the stock. Finally, ValuEngine lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, April 17th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $85.50.

A number of institutional investors have recently made changes to their positions in the business. Conestoga Capital Advisors LLC increased its stake in Omnicell by 5.6% in the first quarter. Conestoga Capital Advisors LLC now owns 1,665,760 shares of the company’s stock valued at $109,241,000 after purchasing an additional 88,016 shares during the last quarter. State Street Corp increased its stake in Omnicell by 8.1% in the first quarter. State Street Corp now owns 1,303,978 shares of the company’s stock valued at $85,515,000 after purchasing an additional 97,154 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Omnicell by 62.3% in the first quarter. Bank of New York Mellon Corp now owns 877,992 shares of the company’s stock valued at $57,578,000 after purchasing an additional 337,035 shares during the last quarter. Waddell & Reed Financial Inc. increased its stake in Omnicell by 16.6% in the first quarter. Waddell & Reed Financial Inc. now owns 637,803 shares of the company’s stock valued at $41,827,000 after purchasing an additional 90,934 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Omnicell by 6.6% in the first quarter. Geode Capital Management LLC now owns 611,079 shares of the company’s stock valued at $40,074,000 after purchasing an additional 37,756 shares during the last quarter. Institutional investors own 95.79% of the company’s stock.

About Omnicell

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

See Also: Investing in Blue-Chip Stocks

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.